Cannara Biotech Inc CFO Nicholas Sosiak joined Steve Darling from Proactive to provided valuable insights into the company’s success in the cannabis industry. Sosiak discussed the company’s strategic acquisitions, including the purchase of a 1 million square foot cannabis facility for $27 million, significantly below its initial cost. Cannara Biotech Inc. has also developed three in-house brands: Tribal, Nugs, and Orchid CBD, each catering to specific market niches. The company places a strong emphasis on consistency and quality to drive brand loyalty among consumers.

Cannara Biotech Inc., a client of our Bristol Investor Relations company, is a vertically integrated producer of premium-grade cannabis and derivative product offerings.

Read the full press release here: Cannara Biotech CFO Nicholas Sosiak: Unveiling Success Strategies and Future Plans